[mwai_chatbot id="default" stream="1" typing="1"]

MASH Mouse Models

Clinically relevant MASH models designed to reproduce steatosis, inflammation, fibrosis, and metabolic dysfunction while supporting efficient study timelines and translational pharmacology research.

Partner with us
12-16 Weeks
Mouse model induction
8-12 Weeks
Hamster model induction
Validated models
Evaluated with benchmark compounds
Robust fibrosis
Designed to support translational MASH research
More information?
Contact us

Designed for Translational MASH Research

BioDuro’s MASH mouse and hamster models are built to reflect key aspects of human disease while supporting efficient study execution, pharmacology evaluation, and therapeutic assessment across metabolic disease programs.

Clinically Relevant Disease Models

Models designed to reproduce key features of human MASH, including steatosis, inflammation, hepatocellular ballooning, fibrosis, dyslipidemia, and metabolic dysfunction.

Short Induction Timelines

Mouse and hamster models support efficient study initiation, helping researchers evaluate therapeutic candidates within practical preclinical timelines.

Translational Validation

Validated with benchmark compounds including OCA, Semaglutide, GFT505, and Resmetirom to support confidence in pharmacology study design and candidate evaluation.

MASH Models Designed to Support Drug Discovery

BioDuro’s MASH platforms provide researchers with flexible options for studying disease progression and therapeutic response across multiple stages of drug discovery.

Mouse MASH Model

A diet-induced model designed to reproduce key metabolic and pathological features of human MASH, including steatosis, inflammation, fibrosis, dyslipidemia, and metabolic dysfunction.

Hamster MASH Model

A clinically relevant hamster model that closely reflects human lipid metabolism and develops hallmark features of MASH, including hepatic steatosis, inflammation, and fibrosis within an efficient induction timeline.

Pharmacology Evaluation

Support efficacy studies across metabolic and liver disease programs using validated mouse and hamster models and clinically relevant study endpoints.

Histopathology & Disease Characterization

Available endpoints include H&E, Oil Red O, and Sirius Red staining, NAS scoring, fibrosis staging, liver enzymes, lipid profiling, glucose metabolism assessments, and fibrosis-related biomarkers.

Validation with Benchmark Therapies

BioDuro’s MASH models have been evaluated using benchmark compounds including OCA, Semaglutide, GFT505, and Resmetirom. These studies demonstrate the ability of the models to capture treatment-related effects across metabolic, biochemical, histological, and fibrosis-related endpoints, helping researchers assess therapeutic potential with greater confidence.

Related Resources

Explore additional resources covering BioDuro’s MASH mouse and hamster models, disease induction strategies, translational validation studies, and pharmacology evaluation approaches. Download the flyer to learn more about model characteristics, benchmark compound performance, and study endpoints supporting metabolic disease research.

See all resources
Q&a: the role of mash models in drug discovery and development
March 15, 2024 Article DMPK

Q&A: The Role of MASH Models in Drug Discovery and Development

Preclinical Models for MASH Disease...
A diet induced high translatable obesogenic mouse mash model
Whitepaper Biology

A Diet-Induced High Translatable Obesogenic Mouse MASH Model: Validation Across Distinct Therapeutic Mechanisms

This whitepaper presents BioDuro’s HFD-induced MASH mouse model, highlighting its ability to reproduce key disease characteristics and demonstrate consistent ...

Looking for a MASH Research Partner?

Whether you’re evaluating a new mechanism, validating a therapeutic hypothesis, or advancing a candidate toward development, BioDuro’s MASH mouse and hamster models can help support your preclinical research goals.

Partner with us